DH
Therapeutic Areas
Eagle Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BARHEMSYS® (amisulpride) injection | Postoperative nausea and vomiting (PONV) | Approved/Commercial |
| BYFAVO® (remimazolam) for injection | Induction and maintenance of procedural sedation | Approved/Commercial |
| First-in-class NCE Pipeline | Oncology and Critical Care | Not Specified |
Leadership Team at Eagle Pharmaceuticals
MG
Michael Graves
Chief Executive Officer & Chairman of the Board
CK
Christopher Krawtschuk
Chief Financial Officer
DO
Daniel O’Connor
Chief Strategy Officer & Head of Corporate Development
JS
Jennifer Simpson, PhD
Lead Independent Director, Board Member
RA
Richard A. Edlin, J.D.
Board Member
RL
Robert L. Glenning
Board Member
LB
Luciana Borio, MD
Board Member
SR
Steven Ratoff
Board Member